Merck & Company, Inc. vs Organigram Global Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
6.1
Neutral
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
OGI
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ low return on equity (5%).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
0 analysts
Fundamentals
MRK
OGI
31.5×
Trailing P/E
12.9×
11.5×
Forward P/E
59.2×
13.6%
Profit Margin
6.5%
76.6%
Gross Margin
35.6%
—
ROE
4.6%
4.9%
Revenue Growth
48.7%
—
Earnings Growth
—
0.28
Beta
1.87
—
Price / Book
—
$277.0B
Market Cap
$200M
$73 – $125
52-Week Range
$1 – $2
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →